Literature DB >> 26237198

Accurate Imputation-Based Screening of Gln368Ter Myocilin Variant in Primary Open-Angle Glaucoma.

Puya Gharahkhani1, Kathryn P Burdon2, Alex W Hewitt3, Matthew H Law1, Emmanuelle Souzeau4, Grant W Montgomery1, Graham Radford-Smith5, David A Mackey6, Jamie E Craig7, Stuart MacGregor1.   

Abstract

PURPOSE: Myocilin (MYOC) is a well-established primary open-angle glaucoma (POAG) risk gene, with rare variants known to have high penetrance. The most common clinically relevant risk variant, Gln368Ter, has an allele frequency of 0.1% to 0.3% in populations of European ancestry. Detection of rare MYOC variants has traditionally been conducted using Sanger sequencing. Here we report the use of genotyping arrays and imputation to assess whether rare variants including Gln368Ter can be reliably detected.
METHODS: A total of 1155 cases with advanced POAG and 1992 unscreened controls genotyped on common variant arrays participated in this study. Accuracy of imputation of Gln368Ter variants was compared with direct sequencing. A genome-wide association study was performed using additive model adjusted for sex and the first six principal components.
RESULTS: We found that although the arrays we used were designed to tag common variants, we could reliably impute the Gln368Ter variant (rs74315329). When tested in 1155 POAG cases and 1992 controls, rs74315329 was strongly associated with risk (odds ratio = 15.53, P = 1.07 × 10-9). All POAG samples underwent full sequencing of the MYOC gene, and we found a sensitivity of 100%, specificity of 99.91%, positive predictive value of 95.65%, and negative predictive value of 100% between imputation and sequencing. Gln368Ter was also accurately imputed in a further set of 1801 individuals without POAG. Among the total set of 3793 (1992 + 1801) individuals without POAG, six were predicted (probability > 95%) to carry the risk variant.
CONCLUSIONS: We demonstrate that some clinically important rare variants can be reliably detected using arrays and imputation. These results have important implications for the detection of clinically relevant incidental findings in ongoing and future studies using arrays.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26237198      PMCID: PMC4525674          DOI: 10.1167/iovs.15-17305

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  41 in total

1.  Adult-onset primary open-angle glaucoma caused by mutations in optineurin.

Authors:  Tayebeh Rezaie; Anne Child; Roger Hitchings; Glen Brice; Lauri Miller; Miguel Coca-Prados; Elise Héon; Theodore Krupin; Robert Ritch; Donald Kreutzer; R Pitts Crick; Mansoor Sarfarazi
Journal:  Science       Date:  2002-02-08       Impact factor: 47.728

2.  Analysis of 15 primary open-angle glaucoma families from Australia identifies a founder effect for the Q368STOP mutation of myocilin.

Authors:  Paul N Baird; Jamie E Craig; Andrea J Richardson; Maree A Ring; Pamela Sim; Sue Stanwix; Simon J Foote; David A Mackey
Journal:  Hum Genet       Date:  2002-11-21       Impact factor: 4.132

3.  PLINK: a tool set for whole-genome association and population-based linkage analyses.

Authors:  Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham
Journal:  Am J Hum Genet       Date:  2007-07-25       Impact factor: 11.025

Review 4.  Glaucoma-associated myocilin: a better understanding but much more to learn.

Authors:  Zachary T Resch; Michael P Fautsch
Journal:  Exp Eye Res       Date:  2008-08-29       Impact factor: 3.467

5.  Myocilin Gln368stop mutation and advanced age as risk factors for late-onset primary open-angle glaucoma.

Authors:  A Angius; P Spinelli; G Ghilotti; G Casu; G Sole; A Loi; A Totaro; L Zelante; P Gasparini; N Orzalesi; M Pirastu; L Bonomi
Journal:  Arch Ophthalmol       Date:  2000-05

6.  Evidence for genetic heterogeneity within eight glaucoma families, with the GLC1A Gln368STOP mutation being an important phenotypic modifier.

Authors:  J E Craig; P N Baird; D L Healey; A I McNaught; P J McCartney; J L Rait; J L Dickinson; L Roe; J H Fingert; E M Stone; D A Mackey
Journal:  Ophthalmology       Date:  2001-09       Impact factor: 12.079

7.  Identification of a gene that causes primary open angle glaucoma.

Authors:  E M Stone; J H Fingert; W L Alward; T D Nguyen; J R Polansky; S L Sunden; D Nishimura; A F Clark; A Nystuen; B E Nichols; D A Mackey; R Ritch; J W Kalenak; E R Craven; V C Sheffield
Journal:  Science       Date:  1997-01-31       Impact factor: 47.728

Review 8.  Definition of glaucoma: clinical and experimental concepts.

Authors:  Robert J Casson; Glyn Chidlow; John P M Wood; Jonathan G Crowston; Ivan Goldberg
Journal:  Clin Exp Ophthalmol       Date:  2012-04-05       Impact factor: 4.207

9.  Gln368STOP myocilin mutation in families with late-onset primary open-angle glaucoma.

Authors:  R R Allingham; J L Wiggs; M A De La Paz; D Vollrath; D A Tallett; B Broomer; K H Jones; E A Del Bono; J Kern; K Patterson; J L Haines; M A Pericak-Vance
Journal:  Invest Ophthalmol Vis Sci       Date:  1998-11       Impact factor: 4.799

Review 10.  Genetic dissection of myocilin glaucoma.

Authors:  Gordon Gong; Omofolasade Kosoko-Lasaki; Gleb R Haynatzki; M Roy Wilson
Journal:  Hum Mol Genet       Date:  2004-02-05       Impact factor: 6.150

View more
  10 in total

1.  Myocilin Gene Gln368Ter Variant Penetrance and Association With Glaucoma in Population-Based and Registry-Based Studies.

Authors:  Xikun Han; Emmanuelle Souzeau; Jue-Sheng Ong; Jiyuan An; Owen M Siggs; Kathryn P Burdon; Stephen Best; Ivan Goldberg; Paul R Healey; Stuart L Graham; Jonathan B Ruddle; Richard A Mills; John Landers; Anna Galanopoulos; Andrew J R White; Robert Casson; David A Mackey; Alex W Hewitt; Puya Gharahkhani; Jamie E Craig; Stuart MacGregor
Journal:  JAMA Ophthalmol       Date:  2019-01-01       Impact factor: 7.389

2.  Myocilin Mutations in Patients With Normal-Tension Glaucoma.

Authors:  Wallace L M Alward; Carly van der Heide; Cheryl L Khanna; Ben R Roos; Sobha Sivaprasad; Jason Kam; Robert Ritch; Andrew Lotery; Robert P Igo; Jessica N Cooke Bailey; Edwin M Stone; Todd E Scheetz; Young H Kwon; Louis R Pasquale; Janey L Wiggs; John H Fingert
Journal:  JAMA Ophthalmol       Date:  2019-05-01       Impact factor: 7.389

Review 3.  Major review: Molecular genetics of primary open-angle glaucoma.

Authors:  Yutao Liu; R Rand Allingham
Journal:  Exp Eye Res       Date:  2017-05-10       Impact factor: 3.467

4.  Differential response and withdrawal profile of glucocorticoid-treated human trabecular meshwork cells.

Authors:  Guorong Li; Gang Cui; W Michael Dismuke; Iris Navarro; Kristin Perkumas; David F Woodward; W Daniel Stamer
Journal:  Exp Eye Res       Date:  2016-12-07       Impact factor: 3.467

5.  Genome-wide meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across ancestries.

Authors:  Puya Gharahkhani; Eric Jorgenson; Pirro Hysi; Anthony P Khawaja; Sarah Pendergrass; Xikun Han; Jue Sheng Ong; Alex W Hewitt; Ayellet V Segrè; John M Rouhana; Andrew R Hamel; Robert P Igo; Helene Choquet; Ayub Qassim; Navya S Josyula; Jessica N Cooke Bailey; Pieter W M Bonnemaijer; Adriana Iglesias; Owen M Siggs; Terri L Young; Veronique Vitart; Alberta A H J Thiadens; Juha Karjalainen; Steffen Uebe; Ronald B Melles; K Saidas Nair; Robert Luben; Mark Simcoe; Nishani Amersinghe; Angela J Cree; Rene Hohn; Alicia Poplawski; Li Jia Chen; Shi-Song Rong; Tin Aung; Eranga Nishanthie Vithana; Gen Tamiya; Yukihiro Shiga; Masayuki Yamamoto; Toru Nakazawa; Hannah Currant; Ewan Birney; Xin Wang; Adam Auton; Michelle K Lupton; Nicholas G Martin; Adeyinka Ashaye; Olusola Olawoye; Susan E Williams; Stephen Akafo; Michele Ramsay; Kazuki Hashimoto; Yoichiro Kamatani; Masato Akiyama; Yukihide Momozawa; Paul J Foster; Peng T Khaw; James E Morgan; Nicholas G Strouthidis; Peter Kraft; Jae H Kang; Chi Pui Pang; Francesca Pasutto; Paul Mitchell; Andrew J Lotery; Aarno Palotie; Cornelia van Duijn; Jonathan L Haines; Chris Hammond; Louis R Pasquale; Caroline C W Klaver; Michael Hauser; Chiea Chuen Khor; David A Mackey; Michiaki Kubo; Ching-Yu Cheng; Jamie E Craig; Stuart MacGregor; Janey L Wiggs
Journal:  Nat Commun       Date:  2021-02-24       Impact factor: 14.919

6.  Characteristics of p.Gln368Ter Myocilin Variant and Influence of Polygenic Risk on Glaucoma Penetrance in the UK Biobank.

Authors:  Nazlee Zebardast; Sayuri Sekimitsu; Jiali Wang; Tobias Elze; Puya Gharahkhani; Brian S Cole; Michael M Lin; Ayellet V Segrè; Janey L Wiggs
Journal:  Ophthalmology       Date:  2021-03-10       Impact factor: 14.277

7.  Ethical Considerations for the Return of Incidental Findings in Ophthalmic Genomic Research.

Authors:  Emmanuelle Souzeau; Kathryn P Burdon; David A Mackey; Alex W Hewitt; Ravi Savarirayan; Margaret Otlowski; Jamie E Craig
Journal:  Transl Vis Sci Technol       Date:  2016-02-09       Impact factor: 3.283

8.  Medical relevance of protein-truncating variants across 337,205 individuals in the UK Biobank study.

Authors:  Christopher DeBoever; Yosuke Tanigawa; Malene E Lindholm; Greg McInnes; Adam Lavertu; Erik Ingelsson; Chris Chang; Euan A Ashley; Carlos D Bustamante; Mark J Daly; Manuel A Rivas
Journal:  Nat Commun       Date:  2018-04-24       Impact factor: 14.919

9.  Matrix Mechanotransduction via Yes-Associated Protein in Human Lamina Cribrosa Cells in Glaucoma.

Authors:  Rory Murphy; Mustapha Irnaten; Alan Hopkins; Jeffrey O'Callaghan; W Daniel Stamer; Abbot F Clark; Deborah Wallace; Colm J O'Brien
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-01-03       Impact factor: 4.799

Review 10.  Myocilin-associated Glaucoma: A Historical Perspective and Recent Research Progress.

Authors:  Ritika Sharma; Abhinav Grover
Journal:  Mol Vis       Date:  2021-08-20       Impact factor: 2.367

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.